Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 14/20 | 0.62 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13958574 | 0.92 | P2RX7 (0.51) | P2RX7P2RX3MEN1KMT2AUSP2 | |
| SCHEMBL4497551 | 0.88 | P2RX7 (0.67) | P2RX7P2RX3MEN1KMT2ALMNA | |
| SCHEMBL13958603 | 0.81 | P2RX7 (0.55) | P2RX7P2RX3MEN1KMT2A | |
| SCHEMBL4504886 | 0.80 | P2RX7 (0.80) | P2RX7P2RX3 | |
| SCHEMBL4505106 | 0.79 | P2RX7 (0.76) | P2RX7P2RX3 | |
| SCHEMBL6617064 | 0.79 | P2RX7 (0.73) | P2RX7P2RX3 | |
| SCHEMBL4508277 | 0.79 | P2RX7 (0.75) | P2RX7P2RX3 | |
| SCHEMBL4493958 | 0.78 | P2RX7 (0.69) | P2RX7P2RX3 | |
| SCHEMBL4513258 | 0.78 | P2RX7 (1.00) | P2RX7P2RX3 | |
| SCHEMBL4507991 | 0.77 | P2RX7 (0.89) | P2RX7P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018133-A1 | Novel Adamantane Derivatives | FORD RHONAN | 2009-01-15 | — | — | US | claimed |
| US-20050090524-A1 | Novel adamantane derivatives | ASTRAZENECA AB (SE) | 2005-04-28 | — | — | US | claimed |
| US-20090018133-A1 | Novel Adamantane Derivatives | FORD RHONAN | 2009-01-15 | — | — | US | disclosed |
| US-20050090524-A1 | Novel adamantane derivatives | ASTRAZENECA AB (SE) | 2005-04-28 | — | — | US | disclosed |
| EP-1490341-A1 | NOVEL ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003080579-A1 | NOVEL ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018133-A1 | Novel Adamantane Derivatives | ADRA1A, ADORA1, ADRA1D | P2RX7 554/4885P2RX3 427/4885MEN1 472/4885 |
| US-20050090524-A1 | Novel adamantane derivatives | ADRA1A, ADORA1, ADRA1D | P2RX7 732/4885P2RX3 595/4885MEN1 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.